Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CRISPR Therapeutics AG CRSP

Healthcare Biotechnology
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this... see more

Recent & Breaking News (NDAQ:CRSP)

Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes

Business Wire March 27, 2023

CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting

GlobeNewswire March 14, 2023

CRISPR Therapeutics Announces Transition of Chief Financial Officer

GlobeNewswire March 13, 2023

CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

GlobeNewswire February 27, 2023

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire February 21, 2023

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 8, 2023

CRISPR Therapeutics to Participate in B. Riley Securities' 3rd Annual Oncology Conference

GlobeNewswire January 11, 2023

CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development

GlobeNewswire December 19, 2022

CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON(TM) Trial of CTX110®

GlobeNewswire December 12, 2022

Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition

Business Wire December 10, 2022

CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference

GlobeNewswire December 1, 2022

CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

GlobeNewswire November 10, 2022

CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting

GlobeNewswire November 3, 2022

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

GlobeNewswire November 1, 2022

CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer

GlobeNewswire October 27, 2022

CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

GlobeNewswire October 5, 2022

CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy

GlobeNewswire September 29, 2022

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130(TM) for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

GlobeNewswire September 28, 2022

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire August 31, 2022

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 8, 2022